SCHEDULE 13G/A: T. Rowe Price Associates Discloses 11.1% Stake in Kenvue Inc.
Beneficial Ownership Disclosure
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 11.1% of Kenvue Inc.'s common stock as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc., an investment adviser, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Kenvue Inc.
- As of March 31, 2025, T. Rowe Price Associates, Inc. beneficially owns an aggregate of 212,798,289 shares of Kenvue Inc. common stock.
- This aggregate amount represents 11.1% of Kenvue Inc.'s class of common stock.
- T. Rowe Price Associates, Inc. holds sole voting power over 200,005,753 shares and sole dispositive power over 212,565,566 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
This document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Kenvue Inc.'s future performance or T. Rowe Price's investment strategy beyond the current ownership stake.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure by a large institutional investor, T. Rowe Price Associates, Inc., indicating its passive ownership stake in Kenvue Inc. Such filings provide transparency into significant holdings by investment firms, which can signal institutional confidence or interest in a company within the consumer health industry. The 11.1% stake is substantial, positioning T. Rowe Price as a key institutional shareholder.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.
- Investment Professionals: Offers insight into the holdings of a major asset manager, potentially informing their own investment decisions.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end date for ownership calculation). |
| 05/14/2025 | Date of signature for the Schedule 13G filing. |
Keywords
Kenvue Inc., T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.